Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 67 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Pentheroudakis, George [Clear All Filters]
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab..
J Cancer Res Clin Oncol. 140(5), 737-48.
(2014). In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients..
PLoS One. 9(6), e99131.
(2014). Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression..
Anticancer Res. 34(9), 4949-62.
(2014).
(2014). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial..
PLoS One. 10(5), e0124612.
(2015). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015).
(2015).
(2015). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). Disease evolution and heterogeneity in bilateral breast cancer..
Am J Cancer Res. 6(11), 2611-2630.
(2016). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016). Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin..
Clin Colorectal Cancer. 15(2), 164-9.
(2016). Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer..
Anticancer Res. 36(12), 6347-6356.
(2016). Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer..
Anticancer Res. 36(5), 2365-78.
(2016). MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer..
J Transl Med. 14(1), 136.
(2016). TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting..
Oncotarget. 7(22), 32731-53.
(2016).
(2016).
(2016). Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group..
J Transl Med. 15(1), 30.
(2017). The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases..
Clin Epigenetics. 9, 46.
(2017). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017). Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers..
Cancer Genomics Proteomics. 14(3), 181-195.
(2017). Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer..
Anticancer Res. 37(5), 2323-2334.
(2017).